Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer D Wu

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|October 2, 2019
Past, Current, and Future of Immunotherapies for Prostate CancerAdeline N Boettcher, Ahmed Usman, Alicia Morgans, et al.
The Journal of Clinical Investigation|August 18, 2004
Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancerJennifer D Wu, Lily M Higgins, Alexander Steinle, et al.
Advanced Healthcare Materials|November 28, 2012
3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitroStephen J Florczyk, Gang Liu, Forrest M Kievit, et al.
Biochemical and Biophysical Research Communications|July 21, 2009
An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit sheddingXuanjun Wang, Ashley D Lundgren, Pragya Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic TumorsShengjun Lu, Jinyu Zhang, Dai Liu, et al.
Immunotherapy|June 22, 2019
CD73: an emerging checkpoint for cancer immunotherapySiqi Chen, Derek A Wainwright, Jennifer D Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumorsJennifer D Wu, Austin Odman, Lily M Higgins, et al.
Science Advances|June 1, 2017
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapyJingyu Zhang, Dai Liu, Guangfu Li, et al.
Journal of Hematology & Oncology|June 11, 2020
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapyFahmin Basher, Payal Dhar, Xin Wang, et al.
Translational Oncology|March 3, 2009
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancerJennifer D Wu, Daniel W Lin, Stephanie T Page, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|October 2, 2019
Past, Current, and Future of Immunotherapies for Prostate CancerAdeline N Boettcher, Ahmed Usman, Alicia Morgans, et al.
The Journal of Clinical Investigation|August 18, 2004
Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancerJennifer D Wu, Lily M Higgins, Alexander Steinle, et al.
Advanced Healthcare Materials|November 28, 2012
3D porous chitosan-alginate scaffolds: a new matrix for studying prostate cancer cell-lymphocyte interactions in vitroStephen J Florczyk, Gang Liu, Forrest M Kievit, et al.
Biochemical and Biophysical Research Communications|July 21, 2009
An six-amino acid motif in the alpha3 domain of MICA is the cancer therapeutic target to inhibit sheddingXuanjun Wang, Ashley D Lundgren, Pragya Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2015
Nonblocking Monoclonal Antibody Targeting Soluble MIC Revamps Endogenous Innate and Adaptive Antitumor Responses and Eliminates Primary and Metastatic TumorsShengjun Lu, Jinyu Zhang, Dai Liu, et al.
Immunotherapy|June 22, 2019
CD73: an emerging checkpoint for cancer immunotherapySiqi Chen, Derek A Wainwright, Jennifer D Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 20, 2005
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumorsJennifer D Wu, Austin Odman, Lily M Higgins, et al.
Science Advances|June 1, 2017
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapyJingyu Zhang, Dai Liu, Guangfu Li, et al.
Journal of Hematology & Oncology|June 11, 2020
Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapyFahmin Basher, Payal Dhar, Xin Wang, et al.
Translational Oncology|March 3, 2009
Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancerJennifer D Wu, Daniel W Lin, Stephanie T Page, et al.
Pageof 5